蒲参胶囊治疗高脂血症的Meta分析

Pushen Capsule in the Treatment of Hyperlipidemia: Meta-analysis of Randomized Controlled Trials

目的:评价蒲参胶囊用于治疗高脂血症的疗效和安全性。方法:全面检索中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊全文数据库与万方数字化期刊全文库,收集蒲参胶囊治疗高脂血症的随机对照试验(RCT),并进行质量评价和Meta分析。结果:共收集到5篇RCT文献,其中1项质量为A级,2项为B级,2项为C级;分析结果显示试验组与对照组之间在改善总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇浓度方面差异无统计学意义,MD(95%CI)分别为-0.02(-0.33,0.29)、-0.08(-0.43,0.26)、-0.00(-0.07,0.07);但在显效率[RR=1.43,95%C(I1.22,1.68)]和改善甘油三酯浓度[MD=-0.36,95%CI;(-0.60,-0.13)]方面差异有统计学意义。结论:基于当前临床研究,蒲参胶囊治疗高脂血症疗效不亚于脂必妥,且在降低甘油三酯浓度方面更显优势。

OBJECTIVE： To review the efficacy and safety of Pushen capsules in the treatment of hyperlipidemia. METHODS： Retrieved from CBM, CNKI, VIP and Wanfang database, RCTs about Pushen capsule in the treatment of hyperlipidemia were gathered. Quality evaluation and meta-analysis were carried out. RESULTS： 5 studies were included. The quality of a study was graded A, 2 were B and the other 2 were C. Meta-analysis indicated that the differences of TC, LDL-C and HDL-C were not significant, MD（95%CI） were -0.02（-0.33,0.29）,-0.08（-0.43,0.26）,-0.00（-0.07,0.07）, respectively. However, the difference of apparent efficiency[RR=1.43,95%CI（1.22,1.68）] and TG was significant[MD=-0.36,95%CI（-0.60,-0.13）]. CONCLUSION： Based on the current clinical evidence, for the treatment of hyperlipidemia, Pushen capsule is as effective as Zhibituo, especially decreasing TG level.